2024-05-20 17:17:41 ET
Summary
- Moderna's individualized neoantigen therapy, mRNA-4157, is a cancer vaccine with potential in multiple cancer types.
- mRNA-4157 has produced compelling results in stage III/IV melanoma patients, where a combination with pembrolizumab reduced the risk of recurrence or death by 49%, relative to pembrolizumab alone.
- Competition exists from BioNTech and Roche's autogene cevumeran, another cancer vaccine, where a readout from a melanoma trial could come in H2'24.
...
Read the full article on Seeking Alpha
For further details see:
Aggressive Strides Forward For Moderna's Cancer Vaccine